{"id":7574,"date":"2025-12-08T08:00:27","date_gmt":"2025-12-08T07:00:27","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7574"},"modified":"2025-12-08T13:57:18","modified_gmt":"2025-12-08T12:57:18","slug":"phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7574\/phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll\/","title":{"rendered":"CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,686,629,703,855,691,690,594,781,850,595],"class_list":["post-7574","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bgb-16673","post-tag-btk","post-tag-btk-degrader","post-tag-cadance-304","post-tag-cdac","post-tag-chimeric-degradation-activation-compound","post-tag-chronic-lymphocytic-leukemia","post-tag-cll-sll","post-tag-relapsed-refractory-cll-sll","post-tag-small-lymphocytic-lymphoma","congress_resource_type-poster","content_type-reading","disease_state-chronic-lymphocytic-leukemia","disease_state-small-lymphocytic-lymphoma","molecule-bgb-16673"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":false,"key_data_presentation_only":false,"key_data_presentation_prioritization":0,"tags":[704,760,781,594,595,850,686,629,703,691,690,855],"visible_tags":[704,781,686],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295784","authors":[6585],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Discover the ASH 2025 poster on phase 3 CaDAnCe-304 study comparing BTK degrader BGB-16673 vs pirtobrutinib in R\/R CLL\/SLL by Meghan C. Thompson et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/11\/ASH2025_phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll.jpeg\", \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/295784\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-08\",  \r\n  \"keywords\": [\"bgb 16673 clinical trial\", \"bgb-16673 phase 3 study results\", \"cadance-304 study\", \"cadance-304 phase 3 trial\", \"phase 3 btk degrader trial\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Meghan C. Thompson, MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll\/\"\r\n  }\r\n}\r\n"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Discover the ASH 2025 poster on phase 3 CaDAnCe-304 study comparing BTK degrader BGB-16673 vs pirtobrutinib in R\/R CLL\/SLL by Meghan C. Thompson et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-cadance-304-study-of-btk-degrader-bgb-16673-vs-pirtobrutinib-in-rr-cll-sll\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/6585"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/855"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/690"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/691"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/703"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/629"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/686"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/850"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/595"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/781"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7574"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}